AAVS1-Puro CAG FUCCI Citations (3)

Originally described in: Fluorescent indicators for continuous and lineage-specific reporting of cell-cycle phases in human pluripotent stem cells.
Chang Y, Hellwarth PB, Randolph LN, Sun Y, Xing Y, Zhu W, Lian XL, Bao X Biotechnol Bioeng. 2020 Apr 11. doi: 10.1002/bit.27352. PubMed Journal

Articles Citing AAVS1-Puro CAG FUCCI

Articles
CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, Bhute VJ, Torregrosa-Allen S, Elzey BD, Won YY, Deng Q, Lian XL, Wang X, Eniola-Adefeso O, Bao X. Nat Commun. 2023 Apr 20;14(1):2266. doi: 10.1038/s41467-023-37872-4. PubMed Associated Plasmids AAVS1-Puro CAG-CLTX CD32a-tm CD3z CAR AAVS1-Puro CAG-CLTX CD32a ITAM CAR AAVS1-Puro CAG-CLTX CD32a ITAM CD3z CAR
Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy. Chang Y, Jin G, Luo W, Luo Q, Jung J, Hummel SN, Torregrosa-Allen S, Elzey BD, Low PS, Lian XL, Bao X. Bioact Mater. 2023 Apr 5;27:168-180. doi: 10.1016/j.bioactmat.2023.03.018. eCollection 2023 Sep. PubMed
Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery. Pan Z, Yao Q, Kong W, Ma X, Tian L, Zhao Y, Zhu S, Chen S, Sun M, Liu J, Jiang S, Ma J, Liu Q, Peng X, Li X, Hong Z, Hong Y, Wang X, Liu J, Zhang J, Zhang W, Sun B, Pahlavan S, Xia Y, Shen W, Liu Y, Jiang W, Xie Z, Kong W, Wang X, Wang K. Cell Stem Cell. 2025 Feb 6;32(2):227-245.e9. doi: 10.1016/j.stem.2024.10.015. Epub 2024 Nov 22. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.